Engflag

Maxeran

Quick links to important sections

Maxeran

Maxeran_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Maxeran

Property Description
Active ingredient Metoclopramide Hydrochloride
Form Tablet, Oral solution, Injectable solution
Pharmacological class Prokinetic agent, Anti-emetic
Common use Relief from nausea and vomiting
Origin Synthetic benzamide derivative

Maxeran is a prescription-only medicine classified as both a prokinetic agent and an anti-emetic, designed to help regulate digestive movement and control the sensation of sickness. Its general purpose is to address gastrointestinal motility disorders and provide relief from nausea and vomiting. This medication is considered an essential medicine and is used in the management of these symptoms.

Defining Maxeran: Composition and Chemical Origin

  • The active ingredient in Maxeran is Metoclopramide, often formulated as Metoclopramide Hydrochloride. Chemically, Metoclopramide is a synthetic compound belonging to the benzamide chemical class, confirming its single-ingredient composition. Maxeran is distinguished by its availability across multiple routes of administration, prepared in several dosage forms including the standard oral tablet and oral solution, as well as an injectable solution (in an ampoule) for parenteral administration.

Pharmacological Class and Purpose

  • Metoclopramide is globally categorized as a prokinetic agent because it stimulates and coordinates muscle contractions in the upper gastrointestinal tract, and as an anti-emetic because it prevents nausea and vomiting. Metoclopramide is used for improving gastric emptying and controlling vomiting. The medication's dual action is vital when a patient needs relief from both the sensation of sickness and the underlying slowed movement of the stomach, making it a solution for managing scenarios where digestive distress causes nausea.

Regulatory References

  1. World Health Organization (WHO)

What side effects are possible with Maxeran?

Maxeran: Possible Side Effects and Safety Information

The official safety information for Maxeran (metoclopramide) structures its risk profile around neurological, psychiatric, and systemic adverse reactions, with constraints related to treatment duration and specific patient populations.

Regulatory Classification of Adverse Reactions

Adverse reactions are formally categorized by frequency in regulatory documents, affecting several System-Organ Classes.

Frequency Classification Examples of Adverse Reactions (SOC)
Very Common Drowsiness, restlessness
Common Diarrhea, asthenia (weakness), depression
Uncommon Bradycardia, hypotension, anxiety, dizziness
Rare Seizures, hyperprolactinemia (leading to galactorrhea, amenorrhea)
Frequency Not Known Tardive Dyskinesia, Neuroleptic Malignant Syndrome (NMS), cardiac arrest

Serious adverse reactions documented in regulatory sources include Tardive Dyskinesia (TD), a potentially irreversible movement disorder, which is a major focus of U.S. label warnings. The risk of TD is explicitly linked to the duration of treatment and cumulative dose, leading regulatory bodies to recommend limiting the use of the medicine to the shortest necessary period.

Population-Specific Safety Notes

The official safety profile includes warnings specific to certain groups. Acute extrapyramidal symptoms are more frequent in children and young adults. Older adults have an increased risk of developing Tardive Dyskinesia with prolonged use. Furthermore, the dose may require adjustment in patients with renal or hepatic impairment due to the potential for drug accumulation and increased risk of adverse effects. Safety-related restrictions mandate that Maxeran is contraindicated in conditions such as gastrointestinal hemorrhage, mechanical obstruction, perforation, or pheochromocytoma, as defined in prescribing information.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Maxeran

Overdose Scope

Property Description based on Regulatory Sources
Documented overdose presentations Overdosage may present with drowsiness, disorientation, confusion, and lethargy. The most frequently noted clinical sign is extrapyramidal reactions (EPS), which regulatory documents state are typically self-limiting and resolve within 24 hours. Seizures and uncontrolled movements are also documented manifestations.
Physiological systems affected (as stated in label) The Central Nervous System (CNS) is primarily affected, leading to altered consciousness and movement disorders. A serious documented risk is Methemoglobinemia, affecting the hematological system, specifically noted in neonates.
Population-specific overdose notes (if applicable) Unintentional overdosage has been reported in infants and children, associated with events including seizures, EPS, and lethargy. Methemoglobinemia is a potentially fatal risk specifically for premature and full-term neonates.
Emergency-response statements (as written in official documents) Regulators mandate to seek immediate medical attention for any suspected overdose. Management is primarily symptomatic and supportive, as no specific antidote is known. The drug should be discontinued immediately upon the onset of severe neurological symptoms.
When immediate medical help is required (label-derived phrasing only) Urgent help must be sought immediately if clinical manifestations of Neuroleptic Malignant Syndrome (NMS)—such as hyperthermia and muscle rigidity—or severe EPS develop.

Overdose Classifications (High-Level)

Property Description based on Regulatory Sources
Severity classification (as defined in official documents) Outcomes range from typically self-limiting extrapyramidal reactions to potentially fatal events, including NMS and Methemoglobinemia.
Regulatory basis (EMA / FDA / etc.) Information derived from official labeling and prescribing information published by government health authorities.

Resulting Overdose Structure

Official overdose statements:

  • Overdosage is formally documented to present with signs of drowsiness, disorientation, extrapyramidal reactions, and seizures.
  • The most severe, potentially fatal, documented outcomes are Neuroleptic Malignant Syndrome (NMS) and Methemoglobinemia in neonates.
  • Management is symptomatic and supportive; the label states no specific antidote is known, though anticholinergic agents may be used to control EPS.

Connection to the overall overdose profile: The official regulatory profile defines metoclopramide overdose through specific neurological manifestations and serious systemic risks, particularly NMS and Methemoglobinemia. It explicitly mandates that urgent medical attention must be sought for any overexposure, detailing that clinical management relies on supportive measures and the immediate discontinuation of the medication.

Therapeutic Uses of Maxeran

Maxeran (metoclopramide) may assist with the management of symptoms related to physical discomfort. This action is relevant for easing symptoms that interfere with daily functioning in certain conditions characterized by periods of heightened symptoms.

Maxeran may be appropriate for adults with symptomatic gastroesophageal reflux disease (GERD) and for diabetic gastroparesis (diabetic gastric stasis). This product supports the relief of symptoms associated with acute or disruptive episodes.

It is commonly used to help with symptom clusters that may include nausea, vomiting, persistent fullness, and heartburn.

The medication is applied across domains where additional symptomatic support is needed. In GERD, it may assist with easing symptoms that become more disruptive during flare-ups. For diabetic gastroparesis, it supports general well-being during symptomatic phases. The overall benefit helps maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Support for symptoms related to physical discomfort

Eligibility and Restrictions for Use

Maxeran (metoclopramide) eligibility is governed by official regulatory documentation that strictly defines which populations are permitted or prohibited from use.

Absolute Contraindications

The medicine is contraindicated in several conditions, including gastrointestinal hemorrhage, mechanical obstruction, or perforation, and in patients with pheochromocytoma, epilepsy, or Parkinson disease. Use is also strictly prohibited for individuals with a known hypersensitivity to the drug.

Age and Organ Function Restrictions

Regulatory agencies have established specific age restrictions. Maxeran is contraindicated in children less than one year of age. Use in pediatric patients aged 1 to 18 years is severely restricted, generally reserved for specific second-line indications and limited to a maximum of five days. Older adults require special consideration and a lower initial dose.

Eligibility is further constrained by organ function. Patients with moderate or severe renal impairment or severe hepatic impairment require a mandatory reduced maintenance dose to prevent drug accumulation. Use during pregnancy and lactation is either conditional or contraindicated by official prescribing information. Treatment duration for all populations is strictly limited (e.g., le 12 weeks) to minimize the risk of neurological complications.

What should I know about interactions with other medicines?

The official regulatory profile for metoclopramide identifies both pharmacokinetic and pharmacodynamic interactions that affect co-administered substances or increase the risk of adverse reactions.

Interaction-Related Restrictions

Co-administration with Levodopa or Dopaminergic Agonists is a formal contraindication due to mutual antagonism. It is restricted for use with Monoamine Oxidase Inhibitors (MAOIs) due to the risk of hypertension, and with other drugs likely to cause Extrapyramidal Reactions (EPS), as this increases the severity of documented movement disorders.

Pharmacodynamic Interactions

Concomitant use with Central Nervous System (CNS) depressants, including alcohol, is documented to potentiate sedative effects. Combination with Serotonergic drugs may increase the risk of serotonin syndrome. Neuroleptics and metoclopramide have an additive effect on the occurrence of EPS. The prokinetic action is antagonized when used with Anticholinergics or Morphine derivatives.

Pharmacokinetic Interactions

Maxeran is primarily metabolized by the CYP2D6 enzyme. Strong CYP2D6 inhibitors (e.g., fluoxetine) increase the systemic exposure and plasma concentration of metoclopramide due to reduced clearance. Due to its prokinetic effect, metoclopramide may alter the absorption of other oral medicines: it is documented to increase Cyclosporine bioavailability while potentially decreasing Digoxin bioavailability.

Population-Specific Notes

Official labeling notes that patients with renal impairment face reduced clearance and potential drug accumulation. Similarly, CYP2D6 Poor Metabolizers exhibit higher systemic metoclopramide concentrations.

Mechanism of Action

How Maxeran Works

Maxeran (metoclopramide) acts on defined biological targets to modulate activity across key physiological pathways in both the central and peripheral nervous systems. Its primary mechanism involves targeted interference with neurotransmitter receptor signaling.

Central Modulation of the Emesis Signaling Cascade

Maxeran's central action is primarily focused on dopamine D2 receptor antagonism, specifically within the Chemoreceptor Trigger Zone (CTZ)—a region responsive to circulating emetogenic stimuli. By blocking D2 signaling here, it restricts the magnitude of the signal transmission to the vomiting center. This initiates a signaling sequence that results in the attenuation of central pathway activation.

Increased Cholinergic Activity and Gastrointestinal Motility

In the digestive tract, Maxeran's mechanism involves peripheral D2 receptor antagonism, which increases the release of acetylcholine (ACh) from nerve endings in the enteric system. Modifying these early molecular steps increases the responsiveness of the smooth muscle, resulting in modified signaling dynamics within the peristaltic pathway. This leads to the physiological effects of an increase in the rate of gastric transit and elevated lower esophageal sphincter (LES) tone.

Dosage and Administration Information

Maxeran (metoclopramide) administration follows specific protocols detailing the approved routes, structured dosing schedules, and strict time constraints. The approved routes of administration include oral (tablet, solution, orally disintegrating forms) and parenteral (Intravenous or Intramuscular injection).

Administration Protocols

Parameter Instruction
Dosing Schedule 10 mg four times daily (q.i.d.) for continuous regimens (e.g., gastroparesis), or up to 10 mg three times daily (t.i.d.) for acute uses.
Timing with Meals Oral doses for fixed regimens must be taken on an empty stomach, specifically 30 minutes before each meal and at bedtime.
Dose Interval A mandatory minimum interval of 6 hours must be respected between any two administrations to control drug accumulation.
Duration Limit The medication is limited to short courses, with a maximum of 5 days for acute conditions and not exceeding 12 weeks for prolonged use.
Special Adjustment Dose reduction, often by 50% or more, is required for patients with diagnosed moderate-to-severe renal or hepatic impairment to ensure proper clearance.

These guidelines impose a structured, short-term use protocol, where the administration frequency and total course duration are strictly limited. Intravenous doses are delivered as a slow bolus, typically administered over a 3-minute period, for standard administration.

Recent Clinical Evidence

Research evidence / Overview of Studies for Maxeran

This overview describes the types of clinical research studies conducted for Maxeran (metoclopramide) and the general patterns observed in those studies, focusing on the types of evidence submitted for administrative review. It is not clinical guidance and does not describe how to use the medication.

Evidence for Managing Diabetic Gastroparesis Symptoms

Research has explored the evaluation of Maxeran in studies of individuals with symptomatic diabetic gastroparesis (delayed stomach emptying). The primary evidence comes from short-term, randomized, controlled trials (RCTs). These studies were used in research exploring how symptoms and objective measures of gastric emptying change over time. Research highlights changes measured during the study period, with data showing patterns related to measures of gastric emptying compared to when a placebo was administered.

Evidence for Symptomatic Gastroesophageal Reflux Disease (GERD)

Research has also explored the evaluation of Maxeran in studies of individuals with symptomatic Gastroesophageal Reflux Disease (GERD). Studies examined outcomes related to physical discomfort (like heartburn) and monitored physiological measures, including changes in the pressure of the Lower Esophageal Sphincter (LES). Findings describe patterns observed in the studies where metoclopramide was associated with changes in LES pressure and objective measures of gastric emptying compared to placebo.

Evidence for Acute Nausea and Vomiting

The research base for Maxeran is extensive in studies of acute nausea and vomiting, relying heavily on numerous randomized controlled trials (RCTs) and comprehensive meta-analyses. Studies monitored outcomes describing episodic or acute changes, primarily focusing on the incidence and severity of vomiting within very short observation windows, usually the first 24 hours. Research highlights changes measured during the study period, with data showing patterns related to the incidence of vomiting that were observed in many of these trials.

Long-Term Studies and What Remains Uncertain

Clinical research has focused predominantly on measuring responses over defined time intervals, meaning the efficacy trials for Maxeran generally have short follow-up durations. The consequence of this research structure is that long-term effects are not fully established and data for long-term outcomes remain insufficient. A key challenge noted in research related to diabetic gastroparesis is that objective, functional outcomes did not always correlate consistently with patient-reported outcomes describing perceived discomfort.

Key Studies & References

  1. WHO Model List of Essential Medicines (Metoclopramide listing context)

Frequently Asked Questions (FAQ)

Common questions about Maxeran (FAQ)

Q: How long does it usually take before Maxeran starts to work?

Official product information describes the onset of action following an oral dose as occurring in the range of 30 to 60 minutes.

Q: How long do the effects of one Maxeran dose typically last?

The pharmacological effects of a single dose are generally described in regulatory documents as persisting for 1 to 2 hours after administration. This duration reflects the period during which the medicine's activity is measurable after administration.

Q: Is it necessary to take Maxeran exactly 30 minutes before a meal?

Official prescribing information states that oral doses for continuous regimens should be taken on an empty stomach, specifically 30 minutes before each meal, as well as at bedtime. This precise timing is specified in labeling to optimize the medicine's action and absorption relative to meals.

Q: Is there a risk of withdrawal symptoms if Maxeran is stopped suddenly?

Official information notes that some patients may experience withdrawal symptoms upon discontinuation of the medicine. These symptoms can include dizziness, nervousness, and headaches.

Q: Can Maxeran affect blood pressure?

Yes, official warnings indicate that Maxeran can affect blood pressure. The medicine may elevate blood pressure (hypertension), and hypotension (low blood pressure) has also been reported as an adverse reaction.

Q: How is Maxeran different from other anti-sickness medicines, like Ondansetron?

Maxeran is classified as a dopamine D₂ receptor antagonist that also works by increasing the release of acetylcholine in the digestive tract. This dual action is the basis for its classification as both a prokinetic (improves movement) agent and an anti-emetic (prevents sickness).

Q: What are the most common non-serious side effects people report?

Very common and common side effects documented in official sources often relate to the central nervous system and digestive system. These include restlessness, drowsiness, fatigue (lassitude), and diarrhea.

Q: Can Maxeran cause unusual side effects like breast enlargement or milk production?

Official warnings note the potential for hyperprolactinemia, a rare endocrine disturbance where prolactin levels increase. This condition may be associated with symptoms such as galactorrhea (milk production) and gynecomastia (breast enlargement) in men.

Q: What should be done if a dose of Maxeran is forgotten or missed?

Regulatory guidance indicates skipping the forgotten dose and taking the next dose at the regularly scheduled time. It is important to respect the minimum time interval between doses and not to double up.

Q: Can Maxeran cause severe headaches?

Official labeling lists headache as a potential side effect. While the specific severity is not always quantified in regulatory documents, the symptom is documented as being associated with Maxeran use.

Q: Why is a limit placed on the total daily amount of Maxeran that can be taken?

Regulatory bodies place strict limits on both the daily dose and the total duration of use (e.g., le 12 weeks). This is because the risk of developing a serious, potentially irreversible movement disorder called Tardive Dyskinesia is known to increase with the total cumulative dose and the length of treatment.

How should Maxeran be stored and disposed of?

How to Store and Dispose of Maxeran

Official regulatory guidelines mandate specific conditions for storing and handling Maxeran (metoclopramide) to ensure product stability.

Storage Requirements

Maxeran must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions to 30 C. The medicine must be kept in the original, tightly closed container and protected from light and moisture.

All liquid forms, including the injection and oral solution, must not be frozen.

Handling and Disposal

The medicine must be kept out of the sight and reach of children.

Unused or expired Maxeran must not be disposed of in household waste or flushed down the toilet. Disposal must follow local regulations or utilize a drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Maxeran found in:

A-Z Index: